These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Inturrisi CE; Colburn WA; Kaiko RF; Houde RW; Foley KM Clin Pharmacol Ther; 1987 Apr; 41(4):392-401. PubMed ID: 3829576 [TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics of methadone maintenance patients: renal clearance in low vs high dosages. Bellward GD Proc West Pharmacol Soc; 1977; 20():483-5. PubMed ID: 19769 [No Abstract] [Full Text] [Related]
9. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Foster DJ; Somogyi AA; White JM; Bochner F Br J Clin Pharmacol; 2004 Jun; 57(6):742-55. PubMed ID: 15151520 [TBL] [Abstract][Full Text] [Related]
10. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Meresaar U; Nilsson MI; Holmstrand J; Anggård E Eur J Clin Pharmacol; 1981; 20(6):473-8. PubMed ID: 7286059 [TBL] [Abstract][Full Text] [Related]
11. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Bellward GD; Warren PM; Howald W; Axelson JE; Abbott FS Clin Pharmacol Ther; 1977 Jul; 22(1):92-9. PubMed ID: 17500 [TBL] [Abstract][Full Text] [Related]
12. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. Elkader AK; Brands B; Dunn E; Selby P; Sproule BA J Clin Psychopharmacol; 2009 Feb; 29(1):77-81. PubMed ID: 19142113 [TBL] [Abstract][Full Text] [Related]
13. Applicability of the Øie-Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase. Yahata M; Ishii Y; Nakagawa T; Watanabe T; Miyawaki I Biopharm Drug Dispos; 2020 Apr; 41(4-5):151-165. PubMed ID: 32187715 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. Moolchan ET; Umbricht A; Epstein D J Addict Dis; 2001; 20(2):55-73. PubMed ID: 11318398 [TBL] [Abstract][Full Text] [Related]
15. Patterns of symptom complaints in methadone maintenance patients. Dyer KR; White JM Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488 [TBL] [Abstract][Full Text] [Related]
16. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Säwe J Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cimetidine in advanced cirrhosis. Grahnén A; Jameson S; Lööf L; Tyllström J; Lindström B Eur J Clin Pharmacol; 1984; 26(3):347-55. PubMed ID: 6734697 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. de Vos JW; Geerlings PJ; van den Brink W; Ufkes JG; van Wilgenburg H Eur J Clin Pharmacol; 1995; 48(5):361-6. PubMed ID: 8641323 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients. Spyker DA; Richmond JD; Scheld WM; Bolton WK Am J Nephrol; 1985; 5(5):355-60. PubMed ID: 4061504 [TBL] [Abstract][Full Text] [Related]
20. Effect of urinary pH on the disposition of methadone in man. Nilsson MI; Widerlöv E; Meresaar U; Anggård E Eur J Clin Pharmacol; 1982; 22(4):337-42. PubMed ID: 6286317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]